Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXFORGE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Treatment of hypertension,Management of hypertension in patients who are not adequately controlled on monotherapy,Initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Hypertension
One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Amlodipine: terminal elimination half-life is 30-50 hours (mean ~35 h), supporting once-daily dosing. Valsartan: terminal half-life is approximately 6 hours, with the combination product dosed once daily due to amlodipine's long half-life.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Amlodipine is extensively metabolized in the liver via CYP3A4 to inactive metabolites. Valsartan is primarily eliminated unchanged in feces and urine; only about 20% is metabolized by CYP2C9.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Valsartan is primarily eliminated via biliary excretion (83%) in feces as unchanged drug; renal excretion accounts for 13% (mostly unchanged). Amlodipine is extensively metabolized in the liver, with 60% of metabolites excreted renally and 20-25% in feces as unchanged drug.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Amlodipine: ~93% bound to plasma proteins. Valsartan: 94-97% bound to serum albumin.
~90%, primarily to albumin
Amlodipine: Vd is approximately 21 L/kg, indicating extensive extravascular distribution. Valsartan: Vd is about 17 L, not weight-adjusted, indicating distribution mainly in plasma and extracellular fluid.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral bioavailability: Amlodipine 64-90%; Valsartan about 25% (with wide interindividual variability). Food decreases valsartan absorption by about 40-50%, but does not affect amlodipine absorption.
Oral: 50–60% (extensive first-pass metabolism)
For GFR 30-60 m L/min: no adjustment. For GFR <30 m L/min: not recommended due to lack of data. Contraindicated if GFR <30 m L/min due to hydrochlorothiazide component.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: not recommended. Child-Pugh C: contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients below 18 years.
Not recommended for pediatric use; safety in children under 12 years not established.
No dose adjustment required based on age alone. Initiate at lower end of dosing range (5/160 mg) due to potential for increased sensitivity to hypotension. Monitor renal function closely.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Exforge contains valsartan, which can cause fetal harm when used during pregnancy. If pregnancy is detected, discontinue Exforge as soon as possible.
None
Fetal toxicity,Hypotension in salt- or volume-depleted patients,Impaired renal function,Hyperkalemia,Angioedema,Hepatic impairment,Severe obstructive coronary artery disease
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Pregnancy,Hypersensitivity to amlodipine, valsartan, or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid grapefruit juice (increases amlodipine AUC by 56%). High-potassium foods (bananas, oranges, spinach) may increase hyperkalemia risk; no specific restriction but monitor intake if renal impairment.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Pregnancy Category D. First trimester: Potential fetal toxicity; risk of malformations not significantly increased based on limited data. Second and third trimesters: Oligohydramnios, fetal renal dysfunction, skull ossification defects, hypotension, hyperkalemia, and anuria due to angiotensin II receptor antagonist (valsartan) component. Amlodipine may cause fetal hypoxia due to uterine hypoperfusion.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
No data on Exforge in breast milk. Valsartan is excreted in rat milk; amlodipine is excreted in human milk (M/P ratio unknown). Due to potential adverse effects in nursing infants (hypotension, renal effects), avoid breastfeeding. If used, monitor infant for hypotension and renal function.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Exforge is contraindicated in pregnancy. No dose adjustment can mitigate fetal risk. Alternative antihypertensive therapy is recommended. If inadvertently used, discontinue immediately and switch to a safe alternative.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
EXFORGE (amlodipine/valsartan) combines a dihydropyridine calcium channel blocker with an angiotensin II receptor blocker. It is contraindicated in pregnancy (fetal nephrotoxicity, oligohydramnios). Monitor serum potassium and renal function, especially in older adults, volume-depleted patients, or those with renal impairment. Avoid use with aliskiren in patients with diabetes or GFR <60 m L/min. Peripheral edema is less than amlodipine alone due to vasodilation balance.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid grapefruit juice as it increases amlodipine levels and risk of hypotension.,Take the same time each day; do not skip doses or double up.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,Report swelling in hands/feet, irregular heartbeat, or signs of angioedema (swelling of face/lips).
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXFORGE vs ALDORIL 15, answered by our medical review team.
EXFORGE is a Antihypertensive that works by Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXFORGE and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXFORGE is: One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXFORGE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXFORGE is classified as Category C. Pregnancy Category D. First trimester: Potential fetal toxicity; risk of malformations not significantly increased based on limited data. Second and third trimesters: Oligohydramni. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.